Literature DB >> 19107622

Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.

Pascal Wolter, Benoit Beuselinck, Steven Pans, Patrick Schöffski.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19107622     DOI： 10.1080/02841860802609574

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  18 in total

1.  Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.

Authors:  Terence C Tang; Shan Man; Ping Xu; Giulio Francia; Kae Hashimoto; Urban Emmenegger; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

Review 2.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

Review 3.  Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Authors:  John M L Ebos; Christina R Lee; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

4.  Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer.

Authors:  Kyung-Jin Yun; Woohyeon Kim; Eun Hee Kim; Min-Hee Kim; Dong-Jun Lim; Moo-Il Kang; Bong-Yun Cha
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09-25

5.  Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.

Authors:  Axel Bex; Eric Jonasch; Arjan W Griffioen; Laurie A Mans; Annemarie M A de Graaf; Patrycja Nowak-Sliwinska; Céline L M M de Hoog; Trees A M de Jong; Florry A Vyth-Dreese; Judy R van Beijnum
Journal:  Clin Cancer Res       Date:  2012-05-09       Impact factor: 12.531

6.  Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.

Authors:  James M G Larkin; Lynda M Pyle; Martin E Gore
Journal:  Oncologist       Date:  2010-11-04

Review 7.  Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

Authors:  Naveen S Vasudev; Andrew R Reynolds
Journal:  Angiogenesis       Date:  2014-01-31       Impact factor: 9.596

Review 8.  Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.

Authors:  Maxine Sun; Alessandro Larcher; Pierre I Karakiewicz
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-29

9.  Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience.

Authors:  Amr Shaaban Hanafy
Journal:  Springerplus       Date:  2016-09-29

10.  The complexity of sunitinib dosing in renal cell cancer patients.

Authors:  Ingrid M E Desar; Sasja F Mulder; Peter F A Mulders; Carla M L van Herpen
Journal:  Transl Androl Urol       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.